-
Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCIHY Wang, RL Gao, KF Dou et al. -
A Prospective, Multicenter, Randomized, Open-label Trial to Compare Efficacy and Safety of Clopidogrel vs. Ticagrelor in Stabilized Patients with Acute Myocardial Infarction after Percutan eous Coronary Intervention: rationale and design of the TALOS-AMI trialM-W Park, CJ Kim, K Chang et al.
-
Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trialJ Silvain, B Lattuca, ALPHEUS investigators et al.
-
Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical PerspectiveG Tersalvi, L Biasco, GM Cioffi et al.
-
A randomized comparison of Coronary Stents according to Short or Prolonged durations of Dual Antiplatelet Therapy in patients with Acute Coronary Syndromes: a pre-specified analysis of the SMART-DATE trialWJ Jang, JB Lee, YB Song et al.
-
Dual Antiplatelet Therapy after PCI in Patients at High Bleeding RiskM Valgimigli, E Frigoli, the MASTER DAPT Investigators et al.
-
Gut microbiota induces high platelet response in patients with ST segment elevation myocardial infarction after ticagrelor treatmentX Zhang, XL Zhang, YL Han et al.
-
Elaborately Engineering a Self-Indicating Dual-Drug Nanoassembly for Site-Specific Photothermal-Potentiated Thrombus Penetration and ThrombolysisZQ Zhao, XB Zhang, HY Zhang et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
